A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks

NCT07748000 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

Raynaud's Phenomenon Secondary to Systemic Sclerosis

Interventions

COMBINATION_PRODUCT: LIQ861 (treprostinil) inhalation powder - Dose Titration Arm
COMBINATION_PRODUCT: LIQ861 (treprostinil) inhalation powder - fixed dose arm

Sponsor

Liquidia Technologies, Inc.